Oxyntomodulin suppresses appetite and reduces food intake in humans.

Oxyntomodulin (OXM) is released from the gut postprandially, in proportion to energy intake, and circulating levels of OXM are elevated in several conditions associated with anorexia. Central injection of OXM reduces food intake and weight gain in rodents, suggesting that OXM signals food ingestion to hypothalamic appetite-regulating circuits. We investigated the effect of iv OXM (3.0 pmol/kg.min) on appetite and food intake in 13 healthy subjects (body mass index, 22.5 +/- 0.9 kg/m(2)) in a randomized, double-blind, placebo-controlled, cross-over study. Infusion of OXM significantly reduced ad libitum energy intake at a buffet meal (mean decrease, 19.3 +/- 5.6%; P < 0.01) and caused a significant reduction in scores for hunger. In addition, cumulative 12-h energy intake was significantly reduced by infusion of OXM (mean decrease, 11.3 +/- 6.2%; P < 0.05). OXM did not cause nausea or affect food palatability. Preprandial levels of the appetite-stimulatory hormone, ghrelin, were significantly suppressed by OXM (mean reduction, 44 +/- 10% of postprandial decrease; P < 0.0001). Elevated levels of endogenous OXM associated with disorders of the gastrointestinal tract may contribute to anorexia.

[1]  John R. Christiansen,et al.  Oxyntomodulin from distal gut , 1989, Digestive Diseases and Sciences.

[2]  Noboru Murakami,et al.  The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. , 2002, Gastroenterology.

[3]  K. Nakao,et al.  Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. , 2002, Endocrinology.

[4]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[5]  Mohammad A Ghatei,et al.  Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. , 2002, American journal of physiology. Endocrinology and metabolism.

[6]  S. Bloom,et al.  Food fails to suppress ghrelin levels in obese humans. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  M. Low,et al.  The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis , 2001, International Journal of Obesity.

[8]  G. Frost,et al.  Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[9]  R. Batterham,et al.  Ghrelin causes hyperphagia and obesity in rats. , 2001, Diabetes.

[10]  D. Smith,et al.  Oxyntomodulin inhibits food intake in the rat. , 2001, Endocrinology.

[11]  A. Astrup,et al.  A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[12]  B. Wisse,et al.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.

[13]  M. Tschöp,et al.  Ghrelin induces adiposity in rodents , 2000, Nature.

[14]  S. Woods,et al.  Central nervous system control of food intake , 2000, Nature.

[15]  Y. Schutz,et al.  Energy and substrate balance, and weight regulation. , 2000 .

[16]  A. Astrup,et al.  Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies , 2000, International Journal of Obesity.

[17]  J. Blundell,et al.  Menstrual cycle and appetite control: implications for weight regulation. , 1997, Human reproduction.

[18]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[19]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[20]  D. Bataille,et al.  Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. , 1993 .

[21]  P. Blache,et al.  Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. , 1992, The Journal of clinical endocrinology and metabolism.

[22]  I. Merchenthaler,et al.  Neurons with access to the general circulation in the central nervous system of the rat: A retrograde tracing study with fluoro-gold , 1991, Neuroscience.

[23]  A. M. Tennissen,et al.  Hunger and appetitive factors during total parenteral nutrition , 1989, Appetite.

[24]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[25]  P. Blache,et al.  Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat. , 1987, Endocrinology.

[26]  J. Frijters,et al.  Life events, emotional eating and change in body mass index. , 1986, International journal of obesity.

[27]  J. Polak,et al.  Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  T. Adrian,et al.  Effect of peptide YY on gastric, pancreatic, and biliary function in humans. , 1985, Gastroenterology.

[29]  F. Sundler,et al.  Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut , 1984, Regulatory Peptides.

[30]  S. Bloom,et al.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. , 1983, The Journal of clinical endocrinology and metabolism.

[31]  V. Mutt,et al.  Isolation of glucagon‐37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno‐ileum: Characterization of the peptide (1982) FEBS Letters 146, 79‐86. , 1982, FEBS letters.

[32]  V. Mutt,et al.  Isolation of glucagon‐37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno‐ileum , 1982 .

[33]  D. Bataille,et al.  Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): A potent inhibitor of pentagastrin-stimulated acid secretion in rats , 1982, Bioscience reports.

[34]  N. Scopinaro,et al.  Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. , 1981, International journal of obesity.

[35]  J. Rehfeld,et al.  Simultaneous recording of the gastro-entero-pancreatic hormonal peptide response to food in man. , 1980, Metabolism: clinical and experimental.

[36]  M. Gregor,et al.  Gut hormones in tropical malabsorption. , 1979, British medical journal.

[37]  D. Garner,et al.  The Eating Attitudes Test: an index of the symptoms of anorexia nervosa , 1979, Psychological Medicine.

[38]  A. Andersen,et al.  Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. , 1979, Scandinavian journal of gastroenterology.

[39]  F. Klipstein,et al.  Factors responsible for weight loss in tropical sprue. , 1977, The American journal of clinical nutrition.

[40]  J. H. Payne,et al.  Surgical treatment of obesity. , 1969, American journal of surgery.

[41]  S. Davidson.  Human nutrition and dietetics , 1969 .